Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 9 clinical trials
Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL (PTCL)

The purpose of this study is to find out whether the combination treatment of romidepsin and oral azacytidine is safe and effective in patients with Peripheral T-Cell Lymphoma (PTCL). This study

  • 5 views
  • 13 Mar, 2022
  • 3 locations
Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas

This phase I trial finds the appropriate parsaclisib dose level in combination with romidepsin for the treatment of T-cell lymphomas that have come back (relapsed) or that have not responded to

large cell lymphoma
romidepsin
neutrophil count
platelet count
hysterectomy
  • 1 views
  • 01 May, 2022
  • 1 location
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

romidepsin (Arm A); durvalumab, pralatrexate, and romidepsin (Arm B); durvalumab and romidepsin (Arm C); or durvalumab and oral 5-azacitidine (Arm D), in patients with peripheral T-cell lymphoma (PTCL). The

romidepsin
neutrophil count
platelet count
peripheral t-cell lymphoma
gilbert's syndrome
  • 39 views
  • 23 Apr, 2022
  • 1 location
A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma

This is a Phase I Trial to assess the feasibility of Romidepsin combined with Brentuximab Vedotin for patients requiring Systemic Therapy for Cutaneous T-cell Lymphoma.

puva
flow cytometry
lymphoma
neutrophil count
cutaneous t-cell lymphoma
  • 2 views
  • 04 Oct, 2022
  • 1 location
A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

combination of romidepsin, CC-486 (5-azacitidine), dexamethasone, and lenalidomide (RAdR) can be given safely to participants with relapsed or treatment refractory TCM. Other

vincristine
cyclophosphamide
flow cytometry
doxorubicin
neutrophil count
  • 0 views
  • 24 Oct, 2022
  • 1 location
Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer (SEPION)

A multi-center, open-label phase I/II study to to determine the safety and tolerability of Azacitidine and/or Romidepsin in combination with nab-Paclitaxel/Gemcitabine in patients with advanced

paclitaxel
ductal adenocarcinoma
breast ductal carcinoma
azacitidine
pancreatic ductal adenocarcinoma
  • 1 views
  • 23 May, 2022
  • 9 locations
Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy

This prospective, open-label, single-arm study will evaluate the efficacy and safety of azacitidine in combination with chidamide in treatment of newly diagnosed peripheral T-cell lymphoma unfit for conventional chemotherapy.

t-cell lymphoma
measurable disease
peripheral t-cell lymphoma
chidamide
  • 0 views
  • 30 Apr, 2022
  • 1 location
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

This pilot phase I trial studies the side effects of direct tumor microinjection and fludeoxyglucose F-18 positron emission tomography (FDG-PET) in testing drug sensitivity in patients with non-Hodgkin lymphoma, Hodgkin lymphoma, or stage IV breast cancer that has returned after a period of improvement or does not respond to treatment. …

breast cancer
stage iv breast cancer
obinutuzumab
nivolumab
neutrophil count
  • 14 views
  • 22 Mar, 2022
  • 1 location
A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma

This research is being done to study the safety of implanting and retrieving a microdevice that releases up to 19 drugs directly within a cancerous lesion as a possible tool to evaluate the effectiveness of several approved cancer drugs against cutaneous T cell lymphoma and peripheral T cell lymphoma

interferon
vorinostat
neutrophil count
retinoids
cutaneous t-cell lymphoma
  • 0 views
  • 04 Oct, 2022
  • 1 location